Citi raised the firm’s price target on Roivant Sciences (ROIV) to $25 from $16 and keeps a Buy rating on the shares. The firm adjusted biotech price targets as part of a Q3 earnings preview.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ROIV:
- Roivant Sciences files automatic mixed securities shelf
- Hold Rating for Roivant Sciences Amid Promising Developments and Competitive Challenges
- 3 Best Stocks to Buy Now, 9/19/2025, According to Top Analysts
- Roivant Sciences price target raised to $16.50 from $12 at BofA
- TD Cowen initiates $23 price target for Roivant Sciences